MFCP and PDAC share significant overlaps in the clinical manifestations (such as upper abdominal pain, nausea, weight loss, jaundice, diabetes, etc.), risk factors (such as alcohol, smoking, etc.), laboratory tests (such as elevated carbohydrate antigen 199 (CA199) and carcinoembryonic antigen (CEA) levels), and imaging findings (such as delayed enhancement) (57, 58). The gene discussed is CEACAM5; the disease is diabetes mellitus.